Patents Examined by Fozia Hamud
-
Patent number: 11053292Abstract: In certain embodiments, this disclosure relates to conjugates comprising a polypeptide of GM-CSF and a polypeptide IL-4. Typically, the GM-CSF and IL-4 are connected by a linker, e.g., polypeptide. In certain embodiments, the disclosure relates to isolated nucleic acids encoding these polypeptide conjugates, vectors comprising nucleic acid encoding polypeptide conjugates, and protein expression systems comprising these vectors such as infectious viral particles and host cells comprising such nucleic acids.Type: GrantFiled: October 2, 2018Date of Patent: July 6, 2021Assignees: Emory University, Children's Healthcare of Atlanta, Inc.Inventors: Jacques Galipeau, Jiusheng Deng
-
Patent number: 11041008Abstract: The present invention provides method for promoting the maturation and export of T cells from thymic tissue by contacting the thymic tissue with supraphysiological levels of interleukin (IL)-15. The present invention also provides methods for preventing, alleviating, reducing, and/or inhibiting lymphopenia or peripheral depletion of lymphocytes in a patient in need thereof by administering to the patient IL-15.Type: GrantFiled: September 6, 2018Date of Patent: June 22, 2021Assignee: The Government of the United States of America as Represented by The Secretary of the Department of Health and Human ServicesInventors: Cristina Bergamaschi, Barbara K. Felber, George N. Pavlakis, Antonio Valentin
-
Patent number: 11034768Abstract: The invention provides methods for treating or preventing asthma and associated conditions in a patient. The methods featured in the invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody.Type: GrantFiled: October 29, 2018Date of Patent: June 15, 2021Assignees: REGENERON PHARMACEUTICALS, INC.Inventors: Nikhil Amin, Neil Graham, Gianluca Pirozzi, Ariel Teper
-
Patent number: 11026994Abstract: SDC2, compositions that comprise SDC2, vectors encoding SDC2 and compounds that modulate expression of SDC2 by cells are used for treatment of mammalian, e.g. human, cells to achieve immunomodulation or for other specific therapeutic interventions. Cells are treated by combining the cells with SDC2, treating the cells with an antibody or fragment thereof that binds SDC2 or modulating expression or activity of SDC2 by the cells. Cells or tissue are derived from treated cells for therapeutic uses based on their immunomodulatory or other therapeutic properties.Type: GrantFiled: January 22, 2019Date of Patent: June 8, 2021Assignee: ORBSEN THERAPEUTICS LIMITEDInventor: Stephen Joseph Elliman
-
Patent number: 11016099Abstract: The present invention relates to the use of components of the IL23 pathway as biomarkers, e.g., IL22, LCN2 and combinations thereof, to stratify or identify populations of patients suffering from IL23-mediated diseases (e.g., Crohn's disease) responsive to treatment with an anti-IL23 antagonist (including, e.g., anti-IL23 antibodies or antigen-binding fragments thereof). Levels of IL23 pathway biomarkers above or below a predetermined threshold can be used, for example, (i) to determine whether a patient with an IL23-mediated disease or disorder such a Crohn's disease is eligible or non-eligible for treatment with a therapeutic agent (e.g., an ant-IL23 antibody), (ii) to determine whether treatment with a certain agent should be commenced, suspended, or modified, (iii) to diagnose whether the IL23-mediated disease is treatable or not treatable with a specific therapeutic agent, or (iv) to predict the outcome of treating the IL23-mediated disease with a specific therapeutic agent.Type: GrantFiled: September 16, 2016Date of Patent: May 25, 2021Assignees: AMGEN INC., MEDIMMUNE, LLCInventors: Robert W. Georgantas, III, Chris Morehouse, Brandon Higgs, Koustubh Ranade, Katie Streicher, William Rees, Meina Liang, Raffaella Faggioni, Jing Li, Inna Vainshtein, Yen-Wah Lee, Jingjing Chen, Robert A. Gasser, Jr.
-
Patent number: 10981983Abstract: The present invention provides an antibody targeted to interleukin 17A (IL-17A), preparation method and the use thereof. In particular, the invention provides a novel anti-IL-17A monoclonal antibody. The antibody of the present invention is capable of binding IL-17A antigen with high specificity, has high affinity and low immunogenicity, and is used for preparing a medicament for preventing or treating an IL-17A-related disease such as various inflammatory or autoimmune diseases.Type: GrantFiled: January 19, 2018Date of Patent: April 20, 2021Assignee: Huabo Biopharm (Shanghai) Co., Ltd.Inventors: Xiangyang Zhu, Mingqing Cai, Haijia Yu, Huifeng Jia, Ling Yu
-
Patent number: 10947308Abstract: The invention relates to stable and non-aggregating compositions comprising an IL-17A binding molecule, in particular a single domain antibody. Such compositions are useful for topical administration in the treatment of disease, for example skin disease or asthma.Type: GrantFiled: July 10, 2017Date of Patent: March 16, 2021Assignee: Crescendo Biologics LimitedInventors: Karen Bannister, Ulla Lashmar, Daniel Pettit, Thomas Sandal
-
Patent number: 10947307Abstract: Formulations comprising an anti-IL-13 antibody are provided, including pharmaceutical formulations and methods of using such formulations.Type: GrantFiled: June 7, 2018Date of Patent: March 16, 2021Assignee: Genentech, IncInventors: Ajay Deshmukh, Joumana Zeid, Thomas M. Scherer
-
Patent number: 10940200Abstract: The present invention provides methods of modulating an immunological disorder or an immune response. The methods include administering to a subject or a cell an effective amount of an autoimmune antigen and an anti-inflammatory cytokine included in an aluminum-based carrier. Compositions including an autoimmune antigen and an anti-inflammatory cytokine included in an aluminum-based carrier are also provided.Type: GrantFiled: September 28, 2016Date of Patent: March 9, 2021Assignee: East Carolina UniversityInventor: Mark D. Mannie
-
Patent number: 10933130Abstract: Disclosed herein is a vaccine comprising an antigen and IL-33. Also disclosed herein is a method for increasing an immune response in a subject in need thereof. Further disclosed herein is a method for treating cancer in a subject in need thereof. The methods may comprise administering the vaccine to the subject.Type: GrantFiled: August 30, 2018Date of Patent: March 2, 2021Assignees: The Trustees of the University of Pennsylvania, Inovio Pharmaceuticals, Inc.Inventors: David Weiner, Daniel Villarreal, Matthew Morrow, Jian Yan
-
Patent number: 10919961Abstract: The invention provides methods and compositions for treating asthma, e.g., mild or moderate asthma, in a subject using an anti-IL-13 antibody, or antigen-binding portion thereof.Type: GrantFiled: June 27, 2017Date of Patent: February 16, 2021Assignee: Abbvie, Inc.Inventor: Catherine Tripp
-
Patent number: 10906952Abstract: The present invention relates to fusion proteins comprising a binding protein and an IL-15 polypeptide as well as uses thereof, pharmaceutical compositions comprising such fusion proteins and a method for producing such fusion proteins.Type: GrantFiled: March 7, 2016Date of Patent: February 2, 2021Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUM, EBERHARD KARLS UNIVERSITÄT TÜBINGENInventors: Jung Gundram, Helmut Salih, Cornelia Lindner, Berit Lochmann
-
Patent number: 10906979Abstract: The present invention provides antibodies that bind to the IL-3 receptor alpha subunit alpha (Il3R?) chain, and compositions comprising such antibodies. The present invention provides methods for inhibiting or reducing an IL3R?-expressing cell population, the methods comprising contacting a population of IL3R?-expressing cells (e.g., cancer cells and/or cancer stem cells) with an antibody that binds to IL3R?. The present invention also provides antibody conjugates comprising an antibody that binds to an IL3R? chain linked to a cytotoxic agent or anticellular agent and compositions comprising such conjugates. The present invention also provides methods for preventing, treating and/or managing a disorder associated with IL3R?-expressing cells (e.g., a hematological cancer), the methods comprising administering to a subject in need thereof an antibody that binds to IL3R?.Type: GrantFiled: April 24, 2019Date of Patent: February 2, 2021Assignee: Stemline Therapeutics, Inc.Inventor: Ivan Bergstein
-
Patent number: 10899833Abstract: Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1? and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.Type: GrantFiled: October 20, 2017Date of Patent: January 26, 2021Assignee: Janssen Biotech, Inc.Inventor: John Simard
-
Patent number: 10898496Abstract: The present invention concerns protection of an organ or tissue outside of the central nervous system following an ischemic episode. In particular aspects, the invention concerns organ preservation for transplantation, angina pectoris, kidney reperfusion injury, and so forth. In specific embodiments, the organ is subjected to an inhibitor of an NCCa-ATP channel that is regulated by SUR1. Exemplary inhibitors include sulfonylurea compounds, such as glibenclamide, for example.Type: GrantFiled: November 16, 2018Date of Patent: January 26, 2021Assignees: University of Maryland, Baltimore, The United States of America as Represented by the Department of Veterans AffairsInventor: J. Marc Simard
-
Patent number: 10894816Abstract: The present invention provides method for promoting the maturation and export of T cells from thymic tissue by contacting the thymic tissue with supraphysiological levels of interleukin (IL)-15. The present invention also provides methods for preventing, alleviating, reducing, and/or inhibiting lymphopenia or peripheral depletion of lymphocytes in a patient in need thereof by administering to the patient IL-15.Type: GrantFiled: May 2, 2018Date of Patent: January 19, 2021Assignee: The Government of the United States of America as Represented by the Secretary of the Department of Health and Human ServicesInventors: George N. Pavlakis, Barbara K. Felber, Antonio Valentin, Cristina Bergamaschi
-
Patent number: 10881612Abstract: Disclosed are positively-charged, cytotoxic nanoparticle compositions comprising immune modulators (such as the toll-like receptor (TLR)-4 ligand, monophosphoryl lipid (MPL)-A), and Interleukin (IL)-12)), which exhibit enhanced uptake by mammalian cancer cells, and cause increased cancer cell death and/or an increased release of cancer antigens following direct injection to populations of cancer or tumor cells. Also disclosed are nanoparticle-vectored, immunomodulatory compositions that stimulate antigen presenting immune cells and T cells, and support the development of anti-cancer immunity in mammalian hosts. The disclosed cationic liposomes represent an important advance in the area of cancer immunotherapeutics.Type: GrantFiled: August 19, 2016Date of Patent: January 5, 2021Assignee: The Methodist HospitalInventors: Rita Elena Serda, Ismail Mustafa Meraz
-
Patent number: 10875917Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat thrombosis in diseases associated with abnormal blood coagulation or fibrinolysis. In preferred embodiments these patients will comprise those exhibiting elevated D-dimer or other coagulation cascade related proteins and optionally will further exhibit elevated C reactive protein prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, et al.Type: GrantFiled: September 14, 2018Date of Patent: December 29, 2020Assignee: VITAERIS, INC.Inventor: Jeffrey T. L. Smith
-
Patent number: 10865230Abstract: The invention features soluble fusion protein complexes comprising at least two soluble fusion proteins. For example, the first fusion protein is an anti-CD3 antibody covalently linked to an interleukin-15 (IL-15) polypeptide or functional fragment thereof. The second fusion protein comprises a binding domain that recognizes disease antigens, wherein this domain is covalently linked to a soluble interleukin-15 receptor alpha (IL-15R?) polypeptide or a functional fragment thereof. One or both of the first and second fusion proteins further includes an immunoglobulin Fc domain or a functional fragment thereof, and the IL-15 domain of first fusion protein binds to the soluble IL-15R? domain of the second fusion protein to form a soluble fusion protein complex. The invention further provides methods for making and using the complexes of the invention.Type: GrantFiled: May 26, 2017Date of Patent: December 15, 2020Assignee: ALTOR BIOSCIENCE, LLCInventors: Bai Liu, Peter Rhode, Hing C. Wong
-
Patent number: 10858426Abstract: The present invention provides means and methods for treating Interleukin 18 (IL-18)-associated diseases and disorders. In particular, the present invention discloses antibodies specific for free IL-18 and IL-18 Binding Protein (IL-18BP) for use in such treatments and for the diagnosis of the indications.Type: GrantFiled: September 5, 2014Date of Patent: December 8, 2020Assignee: AB2 BIO SAInventors: Andrea Pfeifer, Greg Del Val